Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
MWN-AI** Summary
Akari Therapeutics, Plc (Nasdaq: AKTX), a cutting-edge oncology biotechnology firm, is set to showcase its innovative developments at the 2026 Biocom Global Partnering & Investor Conference. The company's CEO, Abizer Gaslightwala, will present on February 25, 2026, at 11:00 AM PST in San Diego, CA. This event represents a key opportunity for Akari to engage with investors and partners, as management will also be available for one-on-one meetings with registered attendees.
Akari Therapeutics specializes in the development of next-generation antibody drug conjugates (ADCs) featuring a unique payload known as PH1, which focuses on RNA splicing. Their flagship candidate, AKTX-101, targets the Trop2 receptor on cancer cells and employs a proprietary linker to deliver the PH1 payload directly into tumors, thereby minimizing off-target effects. This innovative approach culminates in the modulation of RNA splicing— a novel mechanism that has shown promise in preclinical studies by inducing cancer cell death while simultaneously activating both the innate and adaptive immune systems.
Preclinical results have indicated that AKTX-101 exhibits significant activity and extended survival benefits compared to traditional ADCs that utilize tubulin inhibitors and DNA-damaging agents. Furthermore, this candidate has demonstrated potential when used alone or in tandem with checkpoint inhibitors, particularly against key oncogenic drivers like KRAS and BRAF.
In addition to AKTX-101, Akari is also advancing its pipeline with AKTX-102, which targets CEACAM5, a protein expressed in various solid tumors. The company aims to initiate IND enabling studies for AKTX-101, with an eye towards commencing First-In-Human trials by late 2026 or early 2027. For further information, visit www.akaritx.com or connect with the company on social media platforms.
MWN-AI** Analysis
As Akari Therapeutics gears up for its presentation at the 2026 Biocom Global Partnering & Investor Conference, investors should closely observe the developments surrounding this biotechnology firm, particularly its innovative antibody drug conjugates (ADCs). With a strong focus on oncology, Akari is pioneering the use of a novel payload known as PH1, which targets RNA splicing, a significant advancement from conventional ADC payloads that often cause off-target effects.
The company’s lead candidate, AKTX-101, which targets the Trop2 receptor, has displayed promising preclinical data, showing significant efficacy and improved survival rates compared to existing ADCs. This suggests a high potential for successful market penetration if it progresses through clinical trials and regulatory approvals. Investors should note the ongoing IND enabling studies, with hopes to initiate First-In-Human trials by late 2026 or early 2027. This timeline could generate considerable interest and bolster investor confidence.
Further, Akari's research indicates that AKTX-101 may have synergistic effects when used alongside checkpoint inhibitors – an important advantage given the rising trend of combination therapies in oncology. Such features may position Akari well in a competitive market characterized by aggressive R&D from various biotech firms.
Developing a secondary candidate, AKTX-102, targeting CEACAM5, expands Akari's portfolio in a space known for unmet medical needs. Its differentiated approach could provide additional upside if preliminary results mirror those seen with AKTX-101.
In summary, as Akari presents its findings and explores partnerships at the conference, investors should assess the implications of its clinical trial timelines, the unique mechanisms of its drug candidates, and their potential market impacts. The innovative approach to antitumor treatment, if validated through robust clinical trials, could position Akari Therapeutics for substantial growth in the oncology landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA.
Presentation details are as follows:
Date/Time: Wednesday, February 25, 2026, at 11:00 AM PST
Location: Track B
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ**
How does Akari Therapeutics Plc AKTX plan to differentiate its antibody drug conjugates (ADCs) from existing therapies in the oncology market?
What specific advancements in the PH1 payload of Akari Therapeutics Plc AKTX have been observed in preclinical studies that suggest improved efficacy over traditional ADCs?
In what ways does Akari Therapeutics Plc AKTX anticipate the synergy between its lead candidate and existing checkpoint inhibitors will impact treatment protocols for cancer?
What are the milestones Akari Therapeutics Plc AKTX aims to achieve in the IND enabling studies leading up to its First-In-Human trial expected in late 2026 or early 2027?
**MWN-AI FAQ is based on asking OpenAI questions about Akari Therapeutics Plc (NASDAQ: AKTX).
NASDAQ: AKTX
AKTX Trading
-0.35% G/L:
$0.253 Last:
34,484 Volume:
$0.253 Open:
